Seniors’ Access to Critical Medications Act of 2025

HR2484, titled the "Seniors’ Access to Critical Medications Act of 2025," was introduced in the House on March 31, 2025, and subsequently referred to the Committees on Energy and Commerce and Ways and Means. On April 29, 2025, the bill was ordered to be reported out of committee by a vote of 38-7, indicating strong committee support and advancing it to awaiting floor action. The bill establishes a temporary exception, from January 1, 2026, to December 31, 2030, to the physician self-referral prohibition for certain outpatient prescription drugs furnished by a physician practice under the Medicare program. This legislation does not involve direct federal funding or appropriations. Instead, it modifies existing Medicare regulations to allow physicians to dispense specific outpatient prescription drugs directly to patients. This creates a new revenue stream for physician practices by enabling them to capture a portion of the prescription drug market that was previously handled by traditional pharmacies. The mechanism is regulatory relief, not direct financial allocation. Structural winners under this bill are physician practices that can now directly dispense medications, potentially increasing their revenue and patient convenience. Structural losers are traditional pharmacies and pharmacy benefit managers (PBMs) that will face increased competition for dispensing outpatient prescription drugs. Companies like CVS Health Corporation ($CVS), which operates a large pharmacy chain, and potentially Amazon.com, Inc. ($AMZN) through its pharmacy services, could see increased competition. UnitedHealth Group Incorporated ($UNH) and The Cigna Group ($CI), as major health insurers and PBM operators, could also be indirectly affected by shifts in drug dispensing channels. Based on recent market data, CVS Health Corporation ($CVS) is currently at $73.28, showing a +4.48% change over the last 7 days but a -6.88% change over the last 30 days. Amazon.com, Inc. ($AMZN) is at $212.79, with a +5.89% change over 7 days and a -2.81% change over 30 days. UnitedHealth Group Incorporated ($UNH) is at $281.36, with a +7.48% change over 7 days and a -2.57% change over 30 days. The Cigna Group ($CI) is at $275.69, with a +6.82% change over 7 days and a -1.98% change over 30 days. The bill's impact on these companies would stem from the structural shift in the competitive landscape for prescription drug dispensing, rather than immediate price movements tied to this specific legislative action. The next legislative step for HR2484 is consideration by the full House of Representatives. Given its strong committee support, the bill has momentum for floor action. If passed by the House, it would then move to the Senate for consideration. The temporary nature of the exception, set to expire on December 31, 2030, provides a defined period for this market shift.